Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Amarin Corporation highlighted multiple presentations at the ESC Congress 2026 showcasing new data from the REDUCE-IT trial and related mechanistic studies. The findings advance understanding of treatment adherence, cardiovascular outcomes, lipoprotein(a) biology, and coagulation pathways related to icosapent ethyl (IPE). The ESC/ERA 2026 guideline…